2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at ...

BREVARD COUNTY, FLORIDA – Sunday, April 27, 2025, at 1 p.m., the American Legion Post 200, 105 Ocean Blvd., Satellite Beach, ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.

Fugitive businessman Mehul Choksi battles chronic lymphocytic leukemia while facing extradition from Belgium Learn all about ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...